FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980208548> ?p ?o ?g. }

• W1980208548 abstract "Editor—The word limit for lessons of the week can result in removal of discussion points during editing. We considered several of Breay's and Fergus's comments in early versions of our article. Their points are valid, and doctors prescribing bisphosphonates must read the product information and understand what can happen if the prescribing guidelines are not followed.Our cases highlighted severe hypocalcaemia after bisphosphonate treatment, and, although mild hypocalcaemia is a well documented side effect, we are sure that Breay would agree that such dangerously low serum calcium values are not seen in 1-10% of patients treated with bisphosphonates. Experienced doctors treating hypercalcaemia of malignancy commonly use doses of 60-90 mg pamidronate for a calcium concentration around 3.0 mmol/l, and the Novartis sponsored study comparing zoledronic acid and pamidronate in patients with values ≥ 3.0 mmol/l used 90 mg pamidronate.1 Although failure to comply with prescribing recommendations may have contributed to the effects seen in our cases, the inability to mount a normal physiological response as described played a large part in the severe hypocalcaemia.Palmieri et al misquote and wrongly interpret us. At no point did we advocate that “bisphosphonates can be used as prophylaxis against metastatic bone cancer.” We wrote: “Bisphosphonates are increasingly used to treat metabolic bone disease and as prophylaxis against metastatic cancer.”Reviews and meta-analyses of bisphosphonates in cancer have shown clear advantages in terms of reduced skeletal morbidity.2 Guidelines outline the accepted use of these drugs.3 Recent studies have further defined the value of bisphosphonates such as zoledronic acid in several clinical settings and show treatment advantage in reducing skeletal related events in some cancers.4 The study by Saarto et al seems to contradict these findings, but the methodological problems, including a randomisation schedule that resulted in a significant imbalance of hormone receptor positive breast cancers in the two treatment groups,5 are greatly discussed at international meetings. The adverse effect of clodronate on overall survival lost significance in multivariate analysis. Further trials should clarify the position of adjuvant bisphosphonates in treating and preventing cancer related bone disease." @default.
• W1980208548 created "2016-06-24" @default.
• W1980208548 creator A5041050064 @default.
• W1980208548 creator A5059038625 @default.
• W1980208548 creator A5071807128 @default.
• W1980208548 date "2004-06-10" @default.
• W1980208548 modified "2023-09-25" @default.
• W1980208548 title "Hypocalcaemia after intravenous bisphosphonate" @default.
• W1980208548 doi "https://doi.org/10.1136/bmj.328.7453.1439-c" @default.
• W1980208548 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/421836" @default.
• W1980208548 hasPublicationYear "2004" @default.
• W1980208548 type Work @default.
• W1980208548 sameAs 1980208548 @default.
• W1980208548 citedByCount "0" @default.
• W1980208548 crossrefType "journal-article" @default.
• W1980208548 hasAuthorship W1980208548A5041050064 @default.
• W1980208548 hasAuthorship W1980208548A5059038625 @default.
• W1980208548 hasAuthorship W1980208548A5071807128 @default.
• W1980208548 hasBestOaLocation W19802085482 @default.
• W1980208548 hasConcept C121608353 @default.
• W1980208548 hasConcept C126322002 @default.
• W1980208548 hasConcept C177713679 @default.
• W1980208548 hasConcept C2776326535 @default.
• W1980208548 hasConcept C2776541429 @default.
• W1980208548 hasConcept C2777251235 @default.
• W1980208548 hasConcept C2778812048 @default.
• W1980208548 hasConcept C2779399171 @default.
• W1980208548 hasConcept C2779674975 @default.
• W1980208548 hasConcept C519063684 @default.
• W1980208548 hasConcept C71924100 @default.
• W1980208548 hasConceptScore W1980208548C121608353 @default.
• W1980208548 hasConceptScore W1980208548C126322002 @default.
• W1980208548 hasConceptScore W1980208548C177713679 @default.
• W1980208548 hasConceptScore W1980208548C2776326535 @default.
• W1980208548 hasConceptScore W1980208548C2776541429 @default.
• W1980208548 hasConceptScore W1980208548C2777251235 @default.
• W1980208548 hasConceptScore W1980208548C2778812048 @default.
• W1980208548 hasConceptScore W1980208548C2779399171 @default.
• W1980208548 hasConceptScore W1980208548C2779674975 @default.
• W1980208548 hasConceptScore W1980208548C519063684 @default.
• W1980208548 hasConceptScore W1980208548C71924100 @default.
• W1980208548 hasLocation W19802085481 @default.
• W1980208548 hasLocation W19802085482 @default.
• W1980208548 hasOpenAccess W1980208548 @default.
• W1980208548 hasPrimaryLocation W19802085481 @default.
• W1980208548 hasRelatedWork W2030976703 @default.
• W1980208548 hasRelatedWork W2070627971 @default.
• W1980208548 hasRelatedWork W2084405403 @default.
• W1980208548 hasRelatedWork W2106744421 @default.
• W1980208548 hasRelatedWork W2402465612 @default.
• W1980208548 hasRelatedWork W2419587531 @default.
• W1980208548 hasRelatedWork W2748952813 @default.
• W1980208548 hasRelatedWork W2774304749 @default.
• W1980208548 hasRelatedWork W289402102 @default.
• W1980208548 hasRelatedWork W2899084033 @default.
• W1980208548 isParatext "false" @default.
• W1980208548 isRetracted "false" @default.
• W1980208548 magId "1980208548" @default.
• W1980208548 workType "article" @default.